Atorvastatin and Antioxidants for the Treatment of Nonalcoholic Fatty Liver Disease: The St Francis Heart Study Randomized Clinical Trial

[1]  C. Sirlin,et al.  Noninvasive assessment of hepatic steatosis. , 2009, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[2]  N. Chalasani,et al.  Pioglitazone versus vitamin E versus placebo for the treatment of non-diabetic patients with non-alcoholic steatohepatitis: PIVENS trial design. , 2009, Contemporary clinical trials.

[3]  K. Kasturi,et al.  Effect of bariatric surgery on nonalcoholic fatty liver disease: systematic review and meta-analysis. , 2008, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[4]  K. Chayama,et al.  Efficacy of atorvastatin for the treatment of nonalcoholic steatohepatitis with dyslipidemia. , 2008, Metabolism: clinical and experimental.

[5]  G. Marchesini,et al.  Increased risk of cardiovascular disease in non-alcoholic fatty liver disease: causal effect or epiphenomenon? , 2008, Diabetologia.

[6]  R. Xu,et al.  Suspected Nonalcoholic Fatty Liver Disease and Mortality Risk in a Population-Based Cohort Study , 2008, The American Journal of Gastroenterology.

[7]  A. Lonardo,et al.  Statins in liver disease: A molehill, an iceberg, or neither? , 2008, Hepatology.

[8]  M. Manco,et al.  Lifestyle intervention and antioxidant therapy in children with nonalcoholic fatty liver disease: A randomized, controlled trial , 2008, Hepatology.

[9]  Z. Younossi,et al.  Current treatment strategies for non-alcoholic fatty liver disease (NAFLD). , 2007, Current drug discovery technologies.

[10]  R. Karas,et al.  Effect of the magnitude of lipid lowering on risk of elevated liver enzymes, rhabdomyolysis, and cancer: insights from large randomized statin trials. , 2007, Journal of the American College of Cardiology.

[11]  E. Georgescu,et al.  Therapeutic options in non-alcoholic steatohepatitis (NASH). Are all agents alike? Results of a preliminary study. , 2007, Journal of gastrointestinal and liver diseases : JGLD.

[12]  J. Browning.  Statins and hepatic steatosis: Perspectives from the Dallas Heart Study , 2006, Hepatology.

[13]  J. Gisbert,et al.  A pilot study of atorvastatin treatment in dyslipemid, non‐alcoholic fatty liver patients , 2006, Alimentary pharmacology & therapeutics.

[14]  Sang Won Lee,et al.  Macrovesicular hepatic steatosis in living liver donors: use of CT for quantitative and qualitative assessment. , 2006, Radiology.

[15]  G. Farrell,et al.  Nonalcoholic fatty liver disease: From steatosis to cirrhosis , 2006, Hepatology.

[16]  S. Kokkoris,et al.  Rosuvastatin as a novel treatment of non-alcoholic fatty liver disease in hyperlipidemic patients. , 2006, Atherosclerosis.

[17]  A. Lonardo,et al.  Review article: the metabolic syndrome and non‐alcoholic fatty liver disease , 2005, Alimentary pharmacology & therapeutics.

[18]  Y. Arad,et al.  Treatment of asymptomatic adults with elevated coronary calcium scores with atorvastatin, vitamin C, and vitamin E: the St. Francis Heart Study randomized clinical trial. , 2005, Journal of the American College of Cardiology.

[19]  G. Lazaraki,et al.  Efficacy of omega-3 fatty acids, atorvastatin and orlistat in non-alcoholic fatty liver disease with dyslipidemia. , 2004, Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology.

[20]  L. Rallidis,et al.  Pravastatin in patients with nonalcoholic steatohepatitis: results of a pilot study. , 2004, Atherosclerosis.

[21]  A. Peterson,et al.  Statins and Liver Toxicity: A Meta‐Analysis , 2004, Pharmacotherapy.

[22]  J. Hoofnagle,et al.  A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis , 2004, Hepatology.

[23]  S. Gurel,et al.  Ursodeoxycholic acid and atorvastatin in the treatment of nonalcoholic steatohepatitis. , 2003, Canadian journal of gastroenterology = Journal canadien de gastroenterologie.

[24]  P. Hayashi,et al.  Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis , 2003, American Journal of Gastroenterology.

[25]  P. Hayashi,et al.  The natural history of nonalcoholic fatty liver disease: a clinical histopathological study , 2003, American Journal of Gastroenterology.

[26]  C. McClain,et al.  Cytokines and NASH: A pilot study of the effects of lifestyle modification and vitamin E , 2003, Hepatology.

[27]  G. Marchesini,et al.  Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome , 2003, Hepatology.

[28]  Erick M Remer,et al.  The utility of radiological imaging in nonalcoholic fatty liver disease. , 2002, Gastroenterology.

[29]  U. Visco-Comandini,et al.  Metformin in non-alcoholic steatohepatitis , 2002, The Lancet.

[30]  A. Terano,et al.  Plasma transforming growth factor‐β1 level and efficacy of α‐tocopherol in patients with non‐alcoholic steatohepatitis: a pilot study , 2001, Alimentary pharmacology & therapeutics.

[31]  Y. Arad,et al.  Rationale and design of the St. Francis Heart Study: a randomized clinical trial of atorvastatin plus antioxidants in asymptomatic persons with elevated coronary calcification. , 2001, Controlled clinical trials.

[32]  G. Marchesini,et al.  Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. , 2001, Diabetes.

[33]  O. Cummings,et al.  Atorvastatin for the treatment of NASH , 2001 .

[34]  A. Terano,et al.  Plasma transforming growth factor-beta1 level and efficacy of alpha-tocopherol in patients with non-alcoholic steatohepatitis: a pilot study. , 2001, Alimentary pharmacology & therapeutics.

[35]  J. Lavine.  Vitamin E treatment of nonalcoholic steatohepatitis in children: a pilot study. , 2000, The Journal of pediatrics.

[36]  L Dalla Palma,et al.  Noninvasive in vivo quantitative assessment of fat content in human liver. , 1997, Journal of hepatology.